Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBgard is an over-the-counter medical food and dietary supplement specifically formulated for the dietary management of irritable bowel syndrome (IBS). Developed by IM HealthScience (now a part of Nestlé Health Science), it contains ultra-purified peppermint oil (Ultramen®) as its active ingredient, with L-menthol being the primary component. The product utilizes a patented Site-Specific Targeting (SST) technology, which consists of triple-coated, sustained-release microspheres designed to bypass the stomach and release the peppermint oil directly in the small intestine. Its mechanism of action is multifaceted, primarily involving calcium channel antagonism in gastrointestinal smooth muscle to provide antispasmodic effects. It also exhibits anti-inflammatory, carminative, kappa opioid agonist, and serotonergic antagonist properties. IBgard is clinically indicated to manage a combination of IBS symptoms, including abdominal pain, bloating, cramping, and urgency, with an onset of action reported in as little as 24 hours.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IBgard.